Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Investigating the Effect of Cgrp78 Vaccine Against Different Cancer Cells and Its Role in Reducing Melanoma Metastasis Publisher



Zare H1 ; Bakherad H2, 3 ; Esfahani AN2 ; Aghamollaei H4 ; Gargari SLM5 ; Aliomrani M6 ; Ebrahimizadeh W7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  2. 2. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
  5. 5. Department of Biology, Faculty of Basic Science, Shahed University, Tehran, Iran
  6. 6. Department of Pharmacology and Toxicology, Isfahan Pharmaceutical Science Research Center, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  7. 7. Department of Surgery, Division of Urology, McGill University, the Research Institute, the McGill University Health Centre (RI MUHC), Montreal, QC, Canada

Source: Research in Pharmaceutical Sciences Published:2024


Abstract

Background and purpose: Treatment of malignancies with chemotherapy and surgery is often associated with disease recurrence and metastasis. Immunotherapy improves cancer treatment by creating an active response against tumor antigens. Various cancer cells express a large amount of glucose-regulated protein 78 (GRP78) protein on their surface. Stimulating the immune system against this antigen can expose cancer cells to the immune system. Herein, we investigated the effectiveness of a cGRP78-based vaccine against different cancer cells. Experimental approach: BALB/c mice were immunized with the cGRP78. The humoral immune response against different cancer cells was assessed by Cell-ELISA. The cellular immunity response was determined by splenocyte proliferation assay with different cancer antigens. The effect of vaccination on metastasis was investigated in vaccinated mice by injecting melanoma cancer cells into the tail of mice. Findings/Results: These results indicated that the cGRP78 has acceptable antigenicity and stimulates the immune system to produce antibodies. After three injections, the amount of produced antibody was significantly different from the control group. Compared to the other three cell types, Hela and HepG2 showed the highest reaction to the serum of vaccinated mice. Cellular immunity against the B16F10 cell line had the best results compared to other cells. The metastasis results showed that after 30 days, the growth of B16F10 melanoma cancer cells was not noticeable in the lung tissue of vaccinated mice. Conclusion and implications: Considering the resistance of vaccinated mice to metastasis, this vaccine offers a promising prospect for cancer treatment by inhibiting the spread of cancer cells. © 2024 Wolters Kluwer Medknow Publications. All rights reserved.
Related Docs
1. Introduction of a New Recombinant Vaccine Based on Grp78 for Breast Cancer Immunotherapy and Evaluation in a Mouse Model, BioImpacts (2023)
2. Comparison of Mucin-1 in Human Breast Cancer and Canine Mammary Gland Tumor: A Review Study, Cancer Cell International (2022)